Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 [Yahoo! Finance]
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Wells Fargo & Company from $14.00 to $11.00. They now have an "overweight" rating on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Piper Sandler from $43.00 to $30.00. They now have an "overweight" rating on the stock.